Armata Pharmaceuticals (ARMP) investor relations material

Executive summary

• Advanced high-purity, pathogen-specific bacteriophage therapeutics, with three completed Phase 2 trials and a robust pipeline targeting Pseudomonas aeruginosa and Staphylococcus aureus, including AP-SA02's progression toward a pivotal Phase 3 study and manufacturing readiness.

• Achieved significant clinical, regulatory, and manufacturing milestones, including FDA Fast Track and QIDP designations for AP-SA02, submission of a Phase 3 protocol, and agreement on an initial pediatric study plan.

• Secured $2.5M in additional non-dilutive funding, bringing total support to $28.7M, and raised further capital through grants, equity, and debt.

• Promoted David House to CFO and appointed Dr. Daniel B. Gilmer to the Board of Directors.

• Faces substantial doubt about ability to continue as a going concern without further capital.

Financial highlights

• Grant and award revenue for Q2 2026 was $2.5M, up 15.7% year-over-year; $3.3M for the six months, up 24%.

• Operating expenses rose 42.3% year-over-year to $12.8M for Q2 2026, driven by higher R&D and G&A costs.

• Net income for Q2 2026 was $74.1M, compared to a net loss of $16.3M in Q2 2025, primarily due to a $91.0M non-cash gain from the change in fair value of the Convertible Loan.

• Cash and cash equivalents were $24.0M as of June 30, 2026, up from $8.7M at year-end 2025.

• Net loss for the six months ended June 30, 2026 was $41.2M, up from $22.8M in the prior year period.

Outlook and guidance

• Existing cash is insufficient to fund operations for the next 12 months; additional capital will be required through equity, debt, or strategic partnerships.

• Phase 3 trial for AP-SA02 in complicated S. aureus bacteremia expected to initiate in the second half of 2026, contingent on funding.

• Pediatric studies for AP-SA02 deferred until adult safety and efficacy data are available.

• Plans to resume or expand clinical development of other candidates depend on securing further financing.